SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a mix of earnings results and news of Michael Burry's significant short position against the stock, sparking debates about valuation and future growth potential. Community discussions revolve around whether the company is overvalued, with some defending its AI capabilities and government contracts, while others point to its high P/E ratio and the potential impact of Burry's bet.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is seeing increased discussion around a potential market correction, with community members pointing to AI overvaluation and heavy leveraging as potential catalysts for a significant pullback. Traders are actively debating whether this dip is a buying opportunity or the start of a longer-term bearish trend, as they watch key support levels. The conversation also includes concerns about political and economic factors influencing market direction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about its recent earnings and the impact of COVID-era data on trial results for PMO therapies; while some express concern over missed statistical significance, others highlight the revenue beat and potential for Elevidys to replace older treatments. The community is debating the likelihood of FDA action on PMO drugs and the company's overall valuation in light of recent events, with some suggesting a buyout opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending amid mixed sentiment heading into earnings, with discussions around a potential deal with Novo Nordisk for weight-loss drugs like Wegovy. The community is closely watching subscriber growth and margin expansion, while analysts debate the impact of increased competition and past concerns regarding GLP-1s. Some traders are betting on a post-earnings squeeze, while others point to technical indicators suggesting further downside.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending amid community discussion around its recent price movements and potential. Some traders highlight its relative strength as Bitcoin and other cryptos decline, while others remain skeptical, citing its past performance. Discussions include its technology, future potential, and the impact of upcoming announcements.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as traders discuss its potential as 'the better Bitcoin' due to its privacy features and limited supply, with some community members speculating about a short squeeze and a rapid price surge to $1,000.  The conversation also highlights ZEC as a hedge against Bitcoin's volatility, with some suggesting a rotation from BTC into ZEC.  Mentions of its upcoming anniversary and bullish technical indicators add to the current hype.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a post-earnings selloff, with the community debating whether the drop is an overreaction or a sign of deeper issues related to AI spending and future profitability. Sentiment is mixed, ranging from calls to buy the dip to concerns about technicals and potential further declines. Some traders are pointing to historical patterns and oversold conditions as potential catalysts for a bounce.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction, trending as a top crypto, with community members highlighting staking options and a strong, active team. Bullish sentiment is fueled by the project's IRL events, pro athlete sponsorships, and consistent presence on multiple platforms. Discussions also revolve around the supportive community and the potential for significant growth.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market navigates a mixed sentiment driven by AI optimism versus concerns about valuations and economic uncertainty. Community members are actively discussing potential overextension in tech, particularly regarding names like NVDA and PLTR, while also monitoring signals for a possible market correction. News regarding potential impacts from the government shutdown and developments in U.S.-China trade relations are adding to the complex market outlook.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab ($GRAB) is trending due to increased retail investor buzz after the company raised its earnings forecast.  The community is discussing its impressive On-Demand GMV growth and raised full-year revenue guidance.  Some see Grab as an emerging fintech opportunity and a dominant player in the Southeast Asian market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.</li><li>Subscriber count grew 21% to almost 2.5 million, with monthly online revenue per subscriber up 19% to $80.</li><li>On Stocktwits, retail sentiment was ‘extremely bullish,’ with users predicting the stock could climb toward $50 once Novo Nordisk partnership talks conclude.</li></ul>Shares of Hims &amp; Hers Health rose about 5% in after-hours trading on Monday after the company reported another quarter of strong growth and said it’s in talks with Novo Nordisk to bring&nbsp;weight-loss drug Wegovy to its platform.<h2 class="st-heading-2">Revenue And Subscriber Growth Remain Strong</h2>Revenue rose 49% from a year earlier to $599 million as strength continued across the company’s weight-loss and wellness businesses. Net income was $15.8 million, versus $75.6 million a year ago, which had reflected a one-time tax benefit. Adjusted EBITDA increased 53% to $78.4 million.Hims &amp; Hers now has nearly 2.5 million subscribers, up 21% from a year earlier, and monthly revenue per subscriber has also risen 19% to $80. Cash from operations soared to $149 million, while free cash flow for the quarter remained stable at $79 million.Gross margin fell to 74%, from 79% a year earlier, mainly due to changes in shipping cadence and higher production costs related to Hims &amp; Hers’ growing weight-loss portfolio.<h2 class="st-heading-2">Talks With Novo Nordisk</h2>The company said it’s in active talks with Novo Nordisk to make Wegovy injections and an eventual oral formulation available on its platform once they have prescribing approval. No agreement has been reached, and the company said that a deal is not guaranteed.The company said during the earnings call that it expects to bring in over $725 million in weight-loss revenue this year, and that it’s spending money to build new sterile compounding and fulfillment centers to keep up with the surge in demand.<h2 class="st-heading-2">Outlook For 2025</h2>Hims &amp; Hers narrowed its 2025 revenue forecast to a range of $2.335 billion to $2.355 billion, slightly above its previous estimate of $2.3 billion to $2.4 billion. It now expects adjusted EBITDA between $307 million and $317 million, compared with the earlier range of $295 million to $335 million.For the fourth quarter, the company expects revenue of $605 million to $625 million and adjusted EBITDA of $55 million to $65 million. The company said near-term margins will be affected by ongoing investments in its compounding operations and by price adjustments to GLP-1 drugs, though it expects conditions to improve next year as volumes continue to rise.<h2 class="st-heading-2">Stocktwits Traders Bet On Further Gains</h2>On Stocktwits, retail sentiment for Hims was ‘extremely bullish’ amid a 1,734% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/135;" src="https://news.stocktwits-cdn.com/hims_ss_jpg_d349536f51.webp" alt="hims ss.jpg" width="968" height="135"><figcaption>HIMS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed the stock as a solid buy for the next move higher, expecting it to stay above the $30 range.&nbsp;<stembedurl>https://stocktwits.com/Lucy888/message/634788120</stembedurl>Another predicted that shares could climb toward $50 following the company’s strong results and new initiatives. Meanwhile, a third user said the stock could rally sharply once its ongoing discussions with Novo Nordisk are concluded.<stembedurl>https://stocktwits.com/bestest1/message/634776299</stembedurl><stembedurl>https://stocktwits.com/Maximusprofit/message/634778175</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has risen 84% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a HIMS logo is displayed on a smartphone. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Equity

Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 0.00% and +2.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Hims & Hers Health, Inc. (Hims & Hers or the Company, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a...

<ul class="summary-bullets"><li>Hims &amp; Hers Health announced last week that it was providing compounded GLP-1 microdosing treatment plans, giving flexible options to tailor care for those who can benefit.</li><li>The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.</li><li>In late October, KeyBanc initiated coverage of Hims &amp; Hers Health with a ‘Sector Weight’ rating, according to TheFly.</li></ul>Hims &amp; Hers Health (HIMS) is set to report third-quarter results after the markets close on Monday, with investors focusing on the company’s ramp-up of GLP-1 drugs and expansion into more drugs.The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.Retail sentiment on the Hims &amp; Hers remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to data from Stocktwits.<h2 class="st-heading-2">GLP-1 Drugs Expansion</h2>The company last week announced that it was providing compounded GLP-1 microdosing treatment plans, giving flexible options to tailor care for those who can benefit.GLP-1 medications have seen a surge in demand in the U.S. after these drugs, which were developed to treat Type 2 diabetes, have also shown signs to help with weight loss.Last year, the company announced the addition of GLP-1 injections to its comprehensive weight loss portfolio. It had then said that it offers access to GLP-1 injections in addition to weight management oral medication kits.<h2 class="st-heading-2">Analyst Take</h2>In late October, KeyBanc initiated coverage of Hims &amp; Hers stock with a ‘Sector Weight’ rating, according to TheFly. The firm stated it was "intrigued" by the company's international ramp and expansion into more treatments, but believes it may lead to "more muted" margin expansion in 2026.&nbsp;A bullish user on Stocktwits noted that they were expecting a positive free cash flow in the third quarter from the ongoing investments.<a href="https://stocktwits.com/Wolfeyetrader7/message/634703970">https://stocktwits.com/Wolfeyetrader7/message/634703970</a>Shares of Hims &amp; Hers Health have gained nearly 117% in the last 12&nbsp; months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/openai-partners-with-aws-in-38-b-cloud-pact-using-nvidia-gpus/cL2N46zR3zZ">OpenAI Partners With AWS In $38B Cloud Pact To Scale AI Workloads Using Nvidia GPUs</a>

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Q3 Preview: GLP-1 Drug Expansion Draws Investor Focus

The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Hims & Hers Scales AI-Driven Personalized Health and Wellness

HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc. LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc...

Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?

Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.

Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for

Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.

$HIMS Q3 &#39;25 Earnings Results &amp; Recap 
 
Hims &amp; Hers Health Inc reported Q3 &#39;25 revenue of nearly $600 million, beating estimates of $580.24M, and Q4 revenue is expected to be between $605 to $625 million, representing a year over year growth rate of between 26 and 30%.

Stocktwits

 Q3 '25 Earnings Results & Recap 
 
Hims & Hers Health Inc reported Q3 '25 revenue of nearly $600 million, beating estimates of $580.24M, and Q4 revenue is expected to be between $605 to $625 million, representing a year over year growth rate of between 26 and 30%.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$44.64
Prev Close	$45.46
Open	$46.90
Dividend Yield	0.00%
50-Day Moving Average	$51.41
Beta	2.03
Avg. Volume	28.29M
PE Ratio	55.56

52-Week High	$72.98
52-Week Low	$19.15
Market Capitalization	$10.03B
EPS (Annual)	$0.5322
Price to Book	17.81
Revenue Per Employee	$901,963.35
Enterprise Value/EBITDA	N/A

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc